View article

The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD).

Seventeen adolescents aged 11–18 years, diagnosed with ADHD, participated in this 6‐week open‐label study. Duloxetine was given in doses of 30 mg/day in the first week and 60 mg/day from week 2 to the end of the study. Conners' Parent Rating Scale‐Revised (CPRS‐R) short form was used to assess the efficacy of the therapy.

A significant reduction in ADHD symptoms measured by CPRS‐R was observed. This reduction was evident from week 4 of the study. In addition, the decrease was significant in all four subscales of CPRS‐R including inattention, oppositionality, hyperactivity and ADHD index. In terms of side effects, duloxetine was generally safe and well …